Research image darker c2.jpg

Amyloidosis Research Consortium

Accelerating the development of advanced diagnostic tools and effective treatments for systemic amyloidosis through collaboration and innovation


Rare, Underserved and Underdiagnosed


Amyloidosis is a disorder caused by proteins that possess abnormal conformational features leading them to aggregate and infiltrate tissues in the form of amyloid fibrils. Systemic amyloidosis is a disease that can damage the heart, kidneys, liver, soft tissue and nervous system, resulting in multi-organ failure and death. 

Awareness and understanding of these diseases is the first step to delivering better outcomes for patients.


Transform the Research Landscape


The Amyloidosis Research Consortium has been established to address critical needs in clinical trials and related research for the underserved group of systemic amyloid diseases. 

ARC is addressing the urgent, unmet medical needs in amyloidosis.


Optimize, Collaborate and Share


Our Collaborative Network speeds the delivery of new and better therapies to patients with amyloidosis.  This network consists of a highly collaborative team of core amyloidosis centers, devoted to all the types of systemic amyloidosis. 

Find out more about our Clinical Trials Network and Core Member Centers.


Progress through Partnerships


We recognize the complexities of working in ultra rare diseases, and are continually looking at innovative ways to work with and form partnerships between all our stakeholders to further progress.

Join our consortium - partners aligned around one goal, driven by patient needs.